Core Insights - The company, Xianjian Technology, reported a strong revenue growth of approximately 15.5% year-on-year, reaching around RMB 1,267.2 million for the year ending December 31, 2023, with overseas sales increasing significantly by about 36.0% [1][2] - The gross profit was approximately RMB 995.6 million, reflecting a stable gross margin of about 78.6%, while the net profit attributable to shareholders was around RMB 423.3 million, with a net profit margin of approximately 33.4% [1][2] - The company maintained a robust cash position with cash and cash equivalents amounting to approximately RMB 979.3 million, a year-on-year increase of about 17.5% [1] International Business Growth - The international business segment showed strong performance, with sales contributions from overseas markets rising to about 21.7% of total revenue, particularly driven by a 52.9% growth in the European market [1][2] - The company expanded its sales channels to nearly 120 countries and regions globally, enhancing its market penetration [1][2] Domestic Market Performance - The domestic market remains the foundation of the company's operations, contributing approximately 78.3% of total revenue with a year-on-year sales growth of about 10.8% [2] - The company’s structural heart disease products, including left atrial appendage occluders and congenital heart disease occluders, recorded a revenue increase of approximately 25.6% [2] Core Business Segments - The structural heart disease segment generated approximately RMB 495.7 million in sales, with left atrial appendage occluders growing by about 32.0% year-on-year [2] - The peripheral vascular business reported revenue of approximately RMB 707.1 million, a year-on-year increase of about 9.7%, with a notable growth in stent sales [3][4] - The electrophysiology segment achieved sales of approximately RMB 64.4 million, reflecting a growth of about 10.3% [4] Innovation and R&D - The company invested approximately RMB 297.9 million in R&D, marking a year-on-year increase of about 42.9%, to enhance its technological innovation capabilities [5] - Several innovative products received regulatory approvals, including AcuMark™ and Aegisy™ systems, which are expected to drive future growth [6] Strategic Developments - The subsidiary, Yuanxin Technology, completed a strategic financing round, significantly increasing its valuation by 173%, which will support the development of its iron-based bioabsorbable materials [7][8] - The company has submitted multiple products for regulatory approval in various markets, including CE certification in Europe and NMPA approval in China [6][8] Intellectual Property and Recognition - The company has submitted a total of 2,147 patent applications, with 942 patents granted, showcasing its commitment to innovation and intellectual property protection [8] - The company received several industry awards for its innovative products, highlighting its recognition in the medical device sector [8]
先健科技公布2023年度业绩：国际业务增长强劲，创新驱动稳健发展